COVID-19-associated candidiasis and the emerging concern of Candida auris infections

Chin Shiang Tsai, Susan Shin Jung Lee, Wan Chen Chen, Chien Hao Tseng, Nan Yao Lee, Po Lin Chen, Ming Chi Li, Ling Shan Syue, Ching Lung Lo, Wen Chien Ko, Yuan Pin Hung

研究成果: Review article同行評審

10 引文 斯高帕斯(Scopus)


The incidence of COVID-19-associated candidiasis (CAC) is increasing, resulting in a grave outcome among hospitalized patients with COVID-19. The most alarming condition is the increasing incidence of multi-drug resistant Candida auris infections among patients with COVID-19 worldwide. The therapeutic strategy towards CAC caused by common Candida species, such as Candida albicans, Candida tropicalis, and Candida glabrata, is similar to the pre-pandemic era. For non-critically ill patients or those with a low risk of azole resistance, fluconazole remains the drug of choice for candidemia. For critically ill patients, those with a history of recent azole exposure or with a high risk of fluconazole resistance, echinocandins are recommended as the first-line therapy. Several novel therapeutic agents alone or in combination with traditional antifungal agents for candidiasis are potential options in the future. However, for multidrug-resistant C. auris infection, only echinocandins are effective. Infection prevention and control policies, including strict isolation of the patients carrying C. auris and regular screening of non-affected patients, are suggested to prevent the spread of C. auris among patients with COVID-19. Whole-genome sequencing may be used to understand the epidemiology of healthcare-associated candidiasis and to better control and prevent these infections.

頁(從 - 到)672-679
期刊Journal of Microbiology, Immunology and Infection
出版狀態Published - 2023 8月

All Science Journal Classification (ASJC) codes

  • 免疫學和過敏
  • 一般免疫學和微生物學
  • 微生物學(醫學)
  • 傳染性疾病


深入研究「COVID-19-associated candidiasis and the emerging concern of Candida auris infections」主題。共同形成了獨特的指紋。